Drug Type Small molecule drug |
Synonyms SAB402 |
Target |
Action antagonists |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), HER4 antagonists(Receptor tyrosine-protein kinase erbB-4 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC31H28ClFN4O5S2 |
InChIKeyUVWRRZRGHPHHLL-QHCPKHFHSA-N |
CAS Registry2240139-63-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | United States | 01 Aug 2020 |